Eiger BioPharmaceuticals Profit Margin

Eiger BioPharmaceuticals (EIGR) currently reports a profit margin of -4.75% as of December 2023. That compares with -7.18% in the prior-year period — up 33.8% year over year. That is below the Healthcare sector average of 15.52%. Use the charts on this page to explore Eiger BioPharmaceuticals's profit margin history and peer comparisons.

Eiger BioPharmaceuticals's profit margin increased from -7.18% to -4.75% — a 33.8% year-over-year increase (period ending December 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Eiger BioPharmaceuticals's profit margin of -4.75% is lower than the Healthcare sector average of 15.52%. That is roughly 3162.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Eiger BioPharmaceuticals's current -4.75% should be judged against Healthcare norms (sector average: 15.52%) and against EIGR's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -4.75%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.52%. From there, open related valuation or income-statement pages for Eiger BioPharmaceuticals, and consider following EIGR for alerts when major investors trade the stock.